Co-Diagnostics Inc Stock Price, News & Analysis

Co-Diagnostics (NASDAQ: CODX) released its Q2 2025 financial results, reporting revenue of $0.2 million, down from $2.7 million in Q2 2024, primarily due to timing of grant revenue recognition. The company posted a net loss of $7.7 million ($0.23 per share) compared to a $7.6 million loss ($0.25 per share) in Q2 2024.

Operating expenses decreased by 19.1% to $8.2 million, while cash and equivalents stood at $13.4 million. The company remains on track with its Co-Dx PCR platform development, preparing to initiate clinical evaluations for all tests before year-end, with enhanced COVID-19 test trials beginning imminently.

Co-Diagnostics (NASDAQ:CODX), a molecular diagnostics company, has scheduled its second quarter 2025 earnings release for Thursday, August 14, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day.

Key executives participating in the call include CEO Dwight Egan, CFO Brian Brown, and Head of IR Andrew Benson. Investors can access the webcast through the company's IR website and join the conference call via toll-free (888-880-3330) or toll (646-357-8766) numbers. A recording will be available on the company's website for those unable to attend.

Co-Diagnostics (NASDAQ:CODX) announced its participation at WHX Kuala Lumpur, Southeast Asia's leading healthcare exhibition, from July 16-18, 2025 at MITEC. The event, expecting over 10,000 visitors from 54 countries, will serve as a platform for CODX to showcase its PCR diagnostics portfolio.

The company will promote its Co-Primers® technology and introduce its upcoming Co-Dx™ PCR platform, including the Co-Dx PCR MTB test and 8-plex Co-Dx HPV test, both scheduled for clinical evaluations later this year. The company's participation is partially supported by a grant from World Trade Center Utah.

Co-Diagnostics (NASDAQ: CODX) announced its participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City. The conference aims to connect emerging growth companies with institutional investors. Company representatives will engage in one-on-one meetings to showcase their value proposition and introduce their upcoming Co-Dx PCR testing platform.

The company notes that their PCR platform, which includes the PCR Home™, PCR Pro™, mobile app, and associated tests, is currently pending regulatory review by the FDA and other bodies and is not yet commercially available.

Co-Diagnostics (NASDAQ: CODX) reported Q1 2025 financial results with revenue of $0.1 million, down from $0.5 million in Q1 2024 due to lack of grant revenue recognition. The company reduced operating expenses by 18.2% to $8.6 million and reported a net loss of $7.5 million ($0.24 per share), improved from $9.3 million loss in Q1 2024. Cash position stood at $21.5 million as of March 31, 2025. The company remains on track for initiating clinical evaluations of 4 tests in its product pipeline and completing its India manufacturing facility by year-end 2025. These tests include tuberculosis, respiratory multiplex, HPV multiplex, and COVID-19, all designed for use with the Co-Dx PCR Pro platform, which is still pending FDA review.

Co-Diagnostics (NASDAQ: CODX), a molecular diagnostics company known for its patented diagnostic test development platform, has scheduled its first quarter 2025 earnings release for Thursday, May 8, 2025, after market close.

The company will host a conference call and webcast at 4:30 p.m. ET on the same day. Key executives participating include:

• Dwight Egan - Chief Executive Officer
• Brian Brown - Chief Financial Officer
• Andrew Benson - Head of Investor Relations

Investors and analysts can access the event through:

• Webcast: Available on ir.codiagnostics.com (Events & Webcasts page)
• Conference Call: Toll-free (800-715-9871) or Toll (646-307-1963)
• Passcode: 1977478

A recording will be available on the company's website for those unable to attend the live session.

Co-Diagnostics (NASDAQ: CODX) reported its full-year 2024 financial results, showing a decline in revenue to $3.9 million from $6.8 million in 2023. The company's financial performance included:

- Operating expenses of $43.0 million, down 5.2% year-over-year
- Operating loss of $40.1 million
- Net loss of $37.6 million ($1.24 per share)
- Cash position of $29.7 million as of December 31, 2024

Key developments included opening new manufacturing facilities in India and South Salt Lake, and withdrawing their initial FDA 510(k) application for the Co-Dx™ PCR Pro™ Platform to submit an enhanced version. The company plans to commence clinical evaluations for tuberculosis, HPV multiplex, and upper respiratory multiplex tests later in 2025.

Co-Diagnostics (NASDAQ: CODX), a molecular diagnostics company, has scheduled its fourth quarter and full year 2024 earnings release for Thursday, March 27, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day.

Key executives participating in the call include CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. Investors can access the webcast through the company's investor relations website and join the conference call via domestic (844-481-2661) or international (412-317-0652) lines. A recording will be available on the company's website for those unable to attend the live event.

Co-Diagnostics (CODX) has secured a significant legal victory as the United States District Court for the District of Utah granted complete dismissal of a securities class action lawsuit on March 4, 2025. The lawsuit, filed by Gelt Trading on June 15, 2020, alleged violations of Securities Exchange Act sections regarding the company's May 1, 2020 press release about its Logix Smart® COVID-19 test.

The plaintiff claimed that CODX's statement about '100% sensitivity and 100% specificity' was misleading to investors, suggesting the test was perfectly accurate. However, the Court ruled in favor of CODX, concluding that the plaintiff failed to demonstrate loss causation, as none of the three alleged corrective disclosures effectively 'corrected' the May 1 press release or impacted the stock price.

BakerHostetler, representing CODX, successfully argued that the supposedly contradictory information was already known to the market and reflected in the stock price. This dismissal allows the company to focus on its core mission of expanding global access to high-quality molecular diagnostics.